Baseline characteristics by study-qualifying rituximab therapy
| Characteristic . | Rituximab monotherapy (n = 27) . | Rituximab maintenance (n = 45) . | Rituximab-chemotherapy combination (n = 44) . |
|---|---|---|---|
| Median duration of FL, y (range) | 6.4 (1.6-16.7) | 4.3 (1.4-16.4) | 3 (0.5-12.7) |
| Prior regimens ≥ 3, % | 67 | 49 | 43 |
| Received prior chemotherapy, n (%) | 26 (96) | 42 (93) | 43 (98) |
| Refractory to any prior chemotherapy, % | 52 | 42 | 95 |
| Median rituximab doses in qualifying treatment, n (range) | 4 (1-12) | 5 (1-17) | 4 (1-17) |
| Median total rituximab doses, n (range) | 12 (2-19) | 13 (4-34) | 8 (4-24) |
| FLIPI score 3-5, % | 44 | 39 | 56 |
| Bulky disease, %* | 41 | 24 | 32 |
| Characteristic . | Rituximab monotherapy (n = 27) . | Rituximab maintenance (n = 45) . | Rituximab-chemotherapy combination (n = 44) . |
|---|---|---|---|
| Median duration of FL, y (range) | 6.4 (1.6-16.7) | 4.3 (1.4-16.4) | 3 (0.5-12.7) |
| Prior regimens ≥ 3, % | 67 | 49 | 43 |
| Received prior chemotherapy, n (%) | 26 (96) | 42 (93) | 43 (98) |
| Refractory to any prior chemotherapy, % | 52 | 42 | 95 |
| Median rituximab doses in qualifying treatment, n (range) | 4 (1-12) | 5 (1-17) | 4 (1-17) |
| Median total rituximab doses, n (range) | 12 (2-19) | 13 (4-34) | 8 (4-24) |
| FLIPI score 3-5, % | 44 | 39 | 56 |
| Bulky disease, %* | 41 | 24 | 32 |
Bulky disease = largest diameter > 5 cm.